191 related articles for article (PubMed ID: 18957406)
1. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.
Leyton JV; Olafsen T; Sherman MA; Bauer KB; Aghajanian P; Reiter RE; Wu AM
Protein Eng Des Sel; 2009 Mar; 22(3):209-16. PubMed ID: 18957406
[TBL] [Abstract][Full Text] [Related]
2. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.
Leyton JV; Olafsen T; Lepin EJ; Hahm S; Bauer KB; Reiter RE; Wu AM
Clin Cancer Res; 2008 Nov; 14(22):7488-96. PubMed ID: 19010866
[TBL] [Abstract][Full Text] [Related]
3. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
Lepin EJ; Leyton JV; Zhou Y; Olafsen T; Salazar FB; McCabe KE; Hahm S; Marks JD; Reiter RE; Wu AM
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1529-38. PubMed ID: 20354850
[TBL] [Abstract][Full Text] [Related]
4. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.
Olafsen T; Gu Z; Sherman MA; Leyton JV; Witkosky ME; Shively JE; Raubitschek AA; Morrison SL; Wu AM; Reiter RE
J Immunother; 2007; 30(4):396-405. PubMed ID: 17457214
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice.
Fonge H; Leyton JV
Mol Imaging; 2013 May; 12(3):191-202. PubMed ID: 23490445
[TBL] [Abstract][Full Text] [Related]
6. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
7. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
8. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism.
Gu Z; Yamashiro J; Kono E; Reiter RE
Cancer Res; 2005 Oct; 65(20):9495-500. PubMed ID: 16230414
[TBL] [Abstract][Full Text] [Related]
9. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.
Saffran DC; Raitano AB; Hubert RS; Witte ON; Reiter RE; Jakobovits A
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2658-63. PubMed ID: 11226295
[TBL] [Abstract][Full Text] [Related]
10. Humanization of agonistic anti-human 4-1BB monoclonal antibody using a phage-displayed combinatorial library.
Son JH; Lee UH; Lee JJ; Kwon B; Kwon BS; Park JW
J Immunol Methods; 2004 Mar; 286(1-2):187-201. PubMed ID: 15087232
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer.
Foss CA; Fox JJ; Feldmann G; Maitra A; Iacobuzio-Donohue C; Kern SE; Hruban R; Pomper MG
Mol Imaging; 2007; 6(2):131-9. PubMed ID: 17445507
[TBL] [Abstract][Full Text] [Related]
12. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
[TBL] [Abstract][Full Text] [Related]
13. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
[TBL] [Abstract][Full Text] [Related]
14. [
Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
[TBL] [Abstract][Full Text] [Related]
15. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.
Knowles SM; Tavaré R; Zettlitz KA; Rochefort MM; Salazar FB; Jiang ZK; Reiter RE; Wu AM
Clin Cancer Res; 2014 Dec; 20(24):6367-78. PubMed ID: 25326233
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Wang X; Campoli M; Ko E; Luo W; Ferrone S
J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
[TBL] [Abstract][Full Text] [Related]
17. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.
Wu AM; Chen W; Raubitschek A; Williams LE; Neumaier M; Fischer R; Hu SZ; Odom-Maryon T; Wong JY; Shively JE
Immunotechnology; 1996 Feb; 2(1):21-36. PubMed ID: 9373325
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
